Caprion Biosciences Acquires Serametrix Corporation
May 8, 2019
Caprion Biosciences, a GHO Capital portfolio company, has acquired Serametrix Corporation, a CLIA-certified immune monitoring services provider headquartered in Carlsbad, California. The deal expands Caprion's immunology biomarker capabilities—notably Serametrix's MDSC analysis expertise—and extends Caprion's global footprint with Serametrix's operations in the US, UK, Australia and China.
- Buyers
- Caprion Biosciences, GHO Capital Partners LLP
- Targets
- Serametrix Corporation
- Platforms
- Caprion Biosciences
- Industry
- Healthcare Services
- Location
- California, United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
Arsenal Capital Partners Acquires Caprion Biosciences from GHO Capital
July 31, 2019
Healthcare Services
Arsenal Capital Partners has acquired Caprion Biosciences from GHO Capital Partners LLP. Caprion is a specialist laboratory services provider focused on immune monitoring (flow cytometry) and quantitative proteomics for pharmaceutical and biotech R&D, with facilities across North America, Europe and Australia.
-
Cole-Parmer (GTCR Portfolio) Acquires ZeptoMetrix
January 12, 2021
Biotechnology
GTCR’s portfolio company Cole-Parmer has acquired ZeptoMetrix, a Buffalo-based developer and manufacturer of quality control standards and verification panels for molecular diagnostic testing. The acquisition expands Cole-Parmer’s life sciences quality controls and reference standards portfolio and strengthens its capabilities in infectious disease and molecular diagnostics.
-
BioAgilytix Acquires Cambridge Biomedical
November 4, 2019
Healthcare Services
BioAgilytix, a GHO Capital portfolio company, has acquired Cambridge Biomedical, a Cambridge, Massachusetts–based clinical research organisation specializing in large-molecule bioanalysis. The deal expands BioAgilytix's laboratory capacity and capabilities (including CLIA/CAP/GLP capabilities and PCR/molecular suites), broadens its geographic footprint into the Boston/Cambridge biotech cluster, and strengthens its cell- and gene-therapy bioanalytical offerings.
-
Canopy Biosciences Acquires Core Diagnostics
December 4, 2019
Biotechnology
Canopy Biosciences, a St. Louis-based multi-omic services company backed by Ampersand Capital Partners, has acquired Core Diagnostics, a California CLIA-certified biomarker analysis laboratory. The acquisition gives Canopy CLIA-certified laboratory capabilities to offer its multi-omic immune profiling services to clinical as well as preclinical and translational customers.
-
Bruker Corporation Acquires Canopy Biosciences, LLC
September 11, 2020
Biotechnology
Bruker Corporation has acquired Canopy Biosciences, LLC to strengthen its targeted multi-omics and high-plex biomarker imaging capabilities, adding Canopy's ChipCytometry platform and multi-omics services. Financial terms were not disclosed; Ampersand Capital Partners was identified as Canopy's lead investor.
-
Caprion-HistoGeneX Acquires Clinical Logistics Inc.
January 7, 2021
Healthcare Services
Caprion-HistoGeneX, a portfolio company backed by Arsenal Capital Partners, has acquired Clinical Logistics Inc. (CLI), a Halifax-based virtual central specimen management CRO. The acquisition expands Caprion-HistoGeneX’s specimen logistics and kitting capabilities to better support global clinical trial operations and specialty specimen handling for pharmaceutical and biotech customers.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.